News
LKFT
29.78
+0.63%
0.19
Lakefront Biotherapeutics (LKFT) Gets a Hold from Morgan Stanley
TipRanks · 1d ago
Weekly Report: what happened at LKFT last week (0914-0918)?
Weekly Report · 1d ago
Lakefront Biotherapeutics: A Cash Discount With A More Credible Path To Value
Seeking Alpha · 09/15 12:01
Weekly Report: what happened at LKFT last week (0907-0911)?
Weekly Report · 09/14 09:39
Barclays Sticks to Their Sell Rating for Galapagos (0JXZ)
TipRanks · 09/08 06:55
Weekly Report: what happened at LKFT last week (0831-0904)?
Weekly Report · 09/07 09:36
Bernstein Remains a Hold on Galapagos (0JXZ)
TipRanks · 09/02 11:36
Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNTech SE (BNTX)
TipRanks · 08/31 11:50
Weekly Report: what happened at LKFT last week (0824-0828)?
Weekly Report · 08/31 09:40
Acquisition of Own Shares
Barchart · 08/25 15:01
Lakefront's Gamgertamig Receives Orphan Drug Status For Pemphigus
NASDAQ · 08/25 01:33
Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation
Dow Jones · 08/24 20:28
Lakefront Biotherapeutics granted orphan drug designation for gamgertamig
TipRanks · 08/24 20:10
Bank Of America Raises Lakefront Biotherapeutics Stake Above To 10.11%
Benzinga · 08/24 20:02
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Barchart · 08/24 15:01
Lakefront Receives Transparency Notification from Bank of America
Barchart · 08/24 15:01
Morgan Stanley Reaffirms Their Hold Rating on Lakefront Biotherapeutics (LKFT)
TipRanks · 08/24 12:16
Weekly Report: what happened at LKFT last week (0817-0821)?
Weekly Report · 08/24 09:40
Acquisition of Own Shares
Barchart · 08/18 15:01
Weekly Report: what happened at LKFT last week (0810-0814)?
Weekly Report · 08/17 09:41
More
Webull provides a variety of real-time LKFT stock news. You can receive the latest news about Lakefront Biotherapeutics NV through multiple platforms. This information may help you make smarter investment decisions.
About LKFT
Lakefront Biotherapeutics NV is a Belgium‑based company. The Company develops medicines for patients with serious diseases in areas of unmet medical need and uses deal‑making capabilities and capital to identify, acquire, and advance opportunities that create value for patients and shareholders. Its pipeline includes clinical‑stage immunology and oncology programs, such as autoimmune disease candidates and selected oncology assets, primarily advanced through partnerships and targeted development rather than in‑house cell therapy platforms. It builds a portfolio of clinical‑stage therapies intended to support existing treatment approaches and operates across oncology and immunology and inflammation programs supported by clinical proof of concept in emerging therapeutic areas.